Efficacy of comprehensive anti-cancer treatment for lung metastasis after liver transplantation for hepatocellular carcinoma
10.3760/cmn.j.cn421203-20210228-00071
- VernacularTitle:综合抗癌治疗在肝癌肝移植术后肺转移瘤中的疗效观察
- Author:
Li ZHANG
1
;
Jian HE
;
Yan XIE
;
Dazhi TIAN
;
Chiyi CHEN
;
Wentao JIANG
Author Information
1. 天津市第一中心医院移植外科 卫生部危重病急救医学重点实验室 天津市器官移植重点实验室 天津市器官移植临床医学研究中心 中国医学科学院移植医学重点实验室 300192
- Keywords:
Liver transplantation;
Hepatocellular carcinoma;
Metastatic tumor of the lung
- From:
Chinese Journal of Organ Transplantation
2021;42(11):652-656
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of comprehensive anti-cancer treatment for lung metastases after liver transplantation (LT) for hepatocellular carcinoma (HCC).Methods:From March 2012 to July 2016, A total of 36 patients with lung metastasis after LT were divided into comprehensive anti-cancer treatment group (rapamycin + radioactive I 125 seed implantation + pulmonary artery infusion chemotherapy + sorafenib, n=22) and maintenance supportive care group ( n=14). The survival profiles of two groups were evaluated. Results:No significant inter-group differences existed in preoperative basic data, tumor pathology, time of pulmonary metastatic tumor after operation and lung metastasis tumor burden.In comprehensive anti-cancer treatment group, there were partial remission ( n=3), disease stability ( n=12) and disease progression after treatment ( n=7). In maintenance supportive care group, there were disease stability ( n=3) and disease progression after treatment ( n=11). And comprehensive anti-cancer treatment was superior to maintenance supportive care ( χ2=7.901, P=0.019). The median survival time after metastasis was 23 months (95%CI: 19.68-26.32) in comprehensive anti-cancer treatment group and 7 months (95%CI: 3.33-10.67) in maintenance supportive care group; 1-year survival rate 91% and 9%, 2-year survival rate 45% and 0% and 3-year survival rate 10% and 0% respectively.The survival rate of comprehensive anti-cancer treatment group was significantly better than that of maintenance supportive care group ( P<0.001). Conclusions:Comprehensive anti-cancer treatment (rapamycin + radioactive I 125 seed implantation + pulmonary artery infusion chemotherapy + sorafenib) can improve the survival time of patients with lung metastasis after liver transplantation for HCC.
